Literature DB >> 10618125

Quantitation of human immunodeficiency virus type 1 group O load in plasma by measuring reverse transcriptase activity.

J G García Lerma1, V Soriano, A Mas, M E Quiñones-Mateu, E J Arts, W Heneine.   

Abstract

We have evaluated the use of an ultrasensitive reverse transcriptase (RT) activity assay to monitor plasma viremia in two human immunodeficiency virus type 1 (HIV-1) group O-infected patients treated with stavudine, lamivudine, and indinavir. After a initial decline in RT levels observed at 4 weeks of therapy, RT-based plasma viremia returned to baseline values at 28 or 44 weeks of treatment. The rebound in levels of RT activity was associated with the detection of phenotypic resistance to lamivudine and with the Met184Val mutation. Analysis of RT activity in plasma provides a sequence-independent means of monitoring virus loads in HIV-1 group O-infected patients.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10618125      PMCID： PMC88733          DOI： 10.1128/JCM.38.1.402-405.2000

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  16 in total

1.  Virologic, immunologic, and clinical follow-up of a couple infected by the human immunodeficiency virus type one, group O.

Authors:  J N Nkengasong; K Fransen; B Willems; E Karita; J Vingerhoets; L Kestens; R Colebunders; P Piot; G van der Groen
Journal:  J Med Virol       Date:  1997-03       Impact factor: 2.327

2.  Reactivity and amplification efficiency of the NASBA HIV-1 RNA amplification system with regard to different HIV-1 subtypes.

Authors:  E Gobbers; K Fransen; T Oosterlaken; W Janssens; L Heyndrickx; T Ivens; K Vereecken; R Schoones; P van de Wiel; G van der Groen
Journal:  J Virol Methods       Date:  1997-07       Impact factor: 2.014

3.  Characterization of the reverse transcriptase of a human immunodeficiency virus type 1 group O isolate.

Authors:  M E Quiñones-Mateu; V Soriano; E Domingo; L Menéndez-Arias
Journal:  Virology       Date:  1997-09-29       Impact factor: 3.616

4.  Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses.

Authors:  D Descamps; G Collin; F Letourneur; C Apetrei; F Damond; I Loussert-Ajaka; F Simon; S Saragosti; F Brun-Vézinet
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

Review 5.  Trial design in the era of highly effective antiviral drug combinations for HIV infection.

Authors:  V DeGruttola; M Hughes; P Gilbert; A Phillips
Journal:  AIDS       Date:  1998       Impact factor: 4.177

6.  Measurement of human immunodeficiency virus type 1 plasma virus load based on reverse transcriptase (RT) activity: evidence of variabilities in levels of virion-associated RT.

Authors:  J G García Lerma; S Yamamoto; M Gómez-Cano; V Soriano; T A Green; M P Busch; T M Folks; W Heneine
Journal:  J Infect Dis       Date:  1998-05       Impact factor: 5.226

Review 7.  Group O human immunodeficiency virus-1 infections.

Authors:  H W Jaffe; G Schochetman
Journal:  Infect Dis Clin North Am       Date:  1998-03       Impact factor: 5.982

8.  Rapid screening of phenotypic resistance to nevirapine by direct analysis of HIV type 1 reverse transcriptase activity in plasma.

Authors:  G Vázquez-Rosales; J G García Lerma; S Yamamoto; W M Switzer; D Havlir; T M Folks; D D Richman; W Heneine
Journal:  AIDS Res Hum Retroviruses       Date:  1999-09-01       Impact factor: 2.205

9.  Detection of genetically diverse human immunodeficiency virus type 1 group M and O isolates by PCR.

Authors:  R A Respess; A Butcher; H Wang; T Chaowanachan; N Young; N Shaffer; T D Mastro; B Biryahwaho; R Downing; A Tanuri; M Schechter; R Pascu; L Zekeng; L Kaptué; L Gürtler; J Eberle; D Ellenberger; C Fridlund; M Rayfield; S Kwok
Journal:  J Clin Microbiol       Date:  1997-05       Impact factor: 5.948

10.  Detection of reverse transcriptase by a highly sensitive assay in sera from persons infected with human immunodeficiency virus type 1.

Authors:  W Heneine; S Yamamoto; W M Switzer; T J Spira; T M Folks
Journal:  J Infect Dis       Date:  1995-05       Impact factor: 5.226
View more
  3 in total

1.  Comparative performance of three viral load assays on human immunodeficiency virus type 1 (HIV-1) isolates representing group M (subtypes A to G) and group O: LCx HIV RNA quantitative, AMPLICOR HIV-1 MONITOR version 1.5, and Quantiplex HIV-1 RNA version 3.0.

Authors:  P Swanson; V Soriano; S G Devare; J Hackett
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

2.  Relationships between infectious titer, capsid protein levels, and reverse transcriptase activities of diverse human immunodeficiency virus type 1 isolates.

Authors:  Andre J Marozsan; Erika Fraundorf; Awet Abraha; Heather Baird; Dawn Moore; Ryan Troyer; Immaculate Nankja; Eric J Arts
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

3.  Measuring enzymatic HIV-1 susceptibility to two reverse transcriptase inhibitors as a rapid and simple approach to HIV-1 drug-resistance testing.

Authors:  Dieter Hoffmann; Albert D Garcia; P Richard Harrigan; Ian C D Johnston; Tadashi Nakasone; J Gerardo García-Lerma; Walid Heneine
Journal:  PLoS One       Date:  2011-07-20       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.